Fundraising Fox
/Companies
Sign in

Arvelle Therapeutics

Zug, CH · 8 known investors

Find your way into Arvelle Therapeutics

Sign up to see every warm intro you have to Arvelle Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Arvelle Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Angelini Pharma Switzerland is the Swiss arm of a pharmaceutical company focused on brain health and epilepsy, offering prescription treatments for patients and healthcare professionals. Its Swiss portfolio includes the antiepileptic medication Ontozry (cenobamate).

BiotechConsumerHealthtech

Investors · 8

F-Prime Capitallisted by F-Prime CapitalCambridge · $3M – $10M

How we know: F-Prime Capital's portfolio page · Not right? Tell us

H.I.G. Capitallisted by H.I.G. CapitalMiami
H.I.G. HealthBridge Partnerslisted by H.I.G. HealthBridge PartnersMiami · $5M – $40M

How we know: H.I.G. HealthBridge Partners's portfolio page · Not right? Tell us

BRV Capital Managementreported

How we know: european-biotechnology.com · Not right? Tell us

EQT Life SciencesreportedAmsterdam · $11M – $66M

How we know: european-biotechnology.com · Not right? Tell us

H.I.G. BioHealth Partnersreported

How we know: european-biotechnology.com · Not right? Tell us

Also in the syndicate · 1

NovaQuest

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Frequently asked questions

What does Arvelle Therapeutics do?
Angelini Pharma Switzerland is the Swiss arm of a pharmaceutical company focused on brain health and epilepsy, offering prescription treatments for patients and healthcare professionals. Its Swiss portfolio includes the antiepileptic medication Ontozry (cenobamate).
Who are Arvelle Therapeutics's investors?
Arvelle Therapeutics's investors include Andera Partners, F-Prime Capital, H.I.G. Capital, H.I.G. HealthBridge Partners, BRV Capital Management, EQT Life Sciences, H.I.G. BioHealth Partners.
Where is Arvelle Therapeutics headquartered?
Arvelle Therapeutics is headquartered in Zug, CH.